

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
09 June 2022 (09.06.2022)



(10) International Publication Number
WO 2022/117595 A2

(51) International Patent Classification:

C07K 14/245 (2006.01) *A61K 35/74* (2015.01)
A61K 39/00 (2006.01) *A61P 31/04* (2006.01)
A61K 39/108 (2006.01)

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2021/083659

(22) International Filing Date:

30 November 2021 (30.11.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20211337.9 02 December 2020 (02.12.2020) EP
20214942.3 17 December 2020 (17.12.2020) EP

(71) Applicant: **GLAXOSMITHKLINE BIOLOGICALS**

SA [BE/BE]; Rue de l'Institut 89, B-1330 Rixensart (BE).

(72) Inventors: **ADAMO, Roberto**; GSK Vaccines srl, Via

Fiorentina 1, 53100 Siena (IT). **COZZI, Roberta**; GSK
Vaccines srl, Via Fiorentina 1, 53100 Siena (IT). **FAN-**
TONI, Adele; GSK Vaccines srl, Via Fiorentina 1,
53100 Siena (IT). **PHOGAT, Sanjay**; GSK Vaccines srl,
Via Fiorentina 1, 53100 Siena (IT). **ROSINI, Roberto**;
GSK Vaccines srl, Via Fiorentina 1, 53100 Siena (IT).
SCARSELLI, Maria; GSK Vaccines srl, Via Fiorentina
1, 53100 Siena (IT). **WAHOME, Newton**; GlaxoSmithK-
line, 14200 Shady Grove Road, Rockville, Maryland 20850
(US).

(74) Agent: **HITCHCOCK, Lucy**; GlaxoSmithKline, Global

Patents (CN925.1), 980 Great West Road, Brentford Mid-
dlesex TW8 9GS (GB).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: NOVEL ANTIGENS

(57) Abstract: The present invention is directed to novel, modified FimH polypeptides, nucleic acids encoding them, and the use of the polypeptides and nucleic acids in the treatment and/or prevention of disease, in particular, urinary tract infection (UTI).



WO 2022/117595 A2